4basebio (LON:4BB) Releases Earnings Results

4basebio (LON:4BB) released its quarterly earnings data on Monday. The company reported GBX (0.57) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

4basebio Trading Down 2.2%

4BB stock traded down GBX 12.25 on Friday, reaching GBX 550.25. The company’s stock had a trading volume of 912 shares, compared to its average volume of 1,348. The business has a fifty day simple moving average of GBX 514.10 and a two-hundred day simple moving average of GBX 510.40. 4basebio has a 12-month low of GBX 420 and a 12-month high of GBX 820. The firm has a market cap of £85.21 million, a PE ratio of -5.05 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada cut their target price on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research note on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to MarketBeat, 4basebio presently has an average rating of “Buy” and a consensus price target of GBX 1,400.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.